company background image
NXS

Next Science ASX:NXS Stock Report

Last Price

AU$0.75

Market Cap

AU$161.1m

7D

-0.7%

1Y

-39.5%

Updated

04 Oct, 2022

Data

Company Financials +
NXS fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

NXS Stock Overview

Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia.

Next Science Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Next Science
Historical stock prices
Current Share PriceAU$0.75
52 Week HighAU$1.33
52 Week LowAU$0.70
Beta0.87
1 Month Change-20.21%
3 Month Change-6.25%
1 Year Change-39.52%
3 Year Change-73.12%
5 Year Changen/a
Change since IPO-44.44%

Recent News & Updates

Shareholder Returns

NXSAU Medical EquipmentAU Market
7D-0.7%0.9%3.6%
1Y-39.5%-15.6%-8.0%

Return vs Industry: NXS underperformed the Australian Medical Equipment industry which returned -19.3% over the past year.

Return vs Market: NXS underperformed the Australian Market which returned -11.7% over the past year.

Price Volatility

Is NXS's price volatile compared to industry and market?
NXS volatility
NXS Average Weekly Movement11.0%
Medical Equipment Industry Average Movement10.9%
Market Average Movement9.4%
10% most volatile stocks in AU Market16.5%
10% least volatile stocks in AU Market4.2%

Stable Share Price: NXS is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: NXS's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012n/aJudy Mitchellhttps://www.nextscience.com

Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia. The company develops its products using Xbio Technology platform. It offers SURGX, an antimicrobial gel designed for surgical infection management; BACTISURE, a wound lavage that is used to remove biofilm; BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment; and XPERIENCE, an no rinse antimicrobial solution that helps prevent surgical site infections.

Next Science Limited Fundamentals Summary

How do Next Science's earnings and revenue compare to its market cap?
NXS fundamental statistics
Market CapAU$161.09m
Earnings (TTM)-AU$18.02m
Revenue (TTM)AU$16.03m

10.0x

P/S Ratio

-8.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NXS income statement (TTM)
RevenueUS$10.44m
Cost of RevenueUS$2.20m
Gross ProfitUS$8.24m
Other ExpensesUS$19.98m
Earnings-US$11.74m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.055
Gross Margin78.92%
Net Profit Margin-112.40%
Debt/Equity Ratio0%

How did NXS perform over the long term?

See historical performance and comparison